Synthetic Biologics, Inc. (SYN) stock declined over -0.70% intraday to trade at $1.41 a share on AMEX. The stock opened with a gain of 0.71% at $1.46 and touched an intraday high of $1.49, rising 1.44% against the last close of $1.39. The stock went to a low of $1.36 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue0
5Y Sales Change-
Fiscal Year Ends2021-12-30
Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland.
Synthetic Biologics, Inc. (AMEX: SYN) stock price is $1.41 as of the last check on Wednesday, August 10. During the trading session, SYN stock reached the peak price of $1.49 while $1.36 was the lowest point it dropped to.
The AMEX listed SYN is part of Biotechnology industry that operates in the broader Health Care sector. Synthetic Biologics, Inc. , a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need.
Mr. Steven A. Shallcross CPA
CEO, CFO, Treasurer, Corp. Sec. & Director
Dr. Frank Tufaro Ph.D.
Chief Operating Officer
Vincent I. Perrone
Director of Corp. Communication
Dr. Vince Wacher
Head of Product and Corp. Devel.
SYN stock traded closed the last session at $1.42, which is -$0.010000000000000009 or -0.7042253521126767% lower than its previous close of $1.39. SYN's current trading price is 5.19% lower than its 52-week high of $5.57 where as its distance from 52-week low of 1.35% is -74.53%.
Number of SYN employees currently stands at -. SYN operates from 9605 Medical Center Drive, Suite 270, Rockville, MD 20850, United States.
Official Webiste of $SYN is: https://www.syntheticbiologics.com
SYN stock volume for the day was 161,869 shares while in the previous session number of SYN shares traded was 334,987 . The average number of SYN shares traded daily for last 3 months was 187.76 Thousands.
The percentage change in SYN stock occurred in the recent session was -0.7042253521126767% while the dollar amount for the price change in SYN stock was -$0.010000000000000009.
In the recent session, the day high for SYN stock was $1.49 while the low for SYN stock touched on the day was $1.36.
The market value of SYN currently stands at 187.5 Million with its latest stock price at $1.41 and 132.04 Million of its shares outstanding.